vs
PRECISION BIOSCIENCES INC（DTIL）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是PRECISION BIOSCIENCES INC的1.0倍（$35.5M vs $34.2M），PRECISION BIOSCIENCES INC净利率更高（58.9% vs -304.2%，领先363.1%），PRECISION BIOSCIENCES INC同比增速更快（5261.1% vs 681.7%），PRECISION BIOSCIENCES INC自由现金流更多（$-11.3M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 39.5%）
精准生物科学公司是一家上市的美国临床阶段基因编辑企业，总部位于北卡罗来纳州达勒姆，成立于2006年。该公司依托自主研发的ARCUS基因组编辑平台，专注于开发体内和体外两类基因编辑疗法。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
DTIL vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $35.5M |
| 净利润 | $20.1M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 36.6% | -304.8% |
| 净利率 | 58.9% | -304.2% |
| 营收同比 | 5261.1% | 681.7% |
| 净利润同比 | 213.5% | 39.6% |
| 每股收益（稀释后） | $2.62 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $34.2M | $35.5M | ||
| Q3 25 | $13.0K | $5.2M | ||
| Q2 25 | $18.0K | $19.2M | ||
| Q1 25 | $29.0K | $14.7M | ||
| Q4 24 | $638.0K | $4.5M | ||
| Q3 24 | $576.0K | $26.1M | ||
| Q2 24 | $49.9M | $14.4M | ||
| Q1 24 | $17.6M | $13.8M |
| Q4 25 | $20.1M | $-108.1M | ||
| Q3 25 | $-21.8M | $-162.3M | ||
| Q2 25 | $-23.5M | $-171.9M | ||
| Q1 25 | $-20.6M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $-16.4M | $-95.8M | ||
| Q2 24 | $32.7M | $-97.5M | ||
| Q1 24 | $8.6M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 36.6% | -304.8% | ||
| Q3 25 | -158976.9% | -3327.6% | ||
| Q2 25 | -121538.9% | -916.8% | ||
| Q1 25 | -76248.3% | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | -3693.6% | -377.1% | ||
| Q2 24 | 48.4% | -697.4% | ||
| Q1 24 | -23.8% | -698.4% |
| Q4 25 | 58.9% | -304.2% | ||
| Q3 25 | -167476.9% | -3135.3% | ||
| Q2 25 | -130666.7% | -894.2% | ||
| Q1 25 | -70913.8% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | -2851.6% | -367.5% | ||
| Q2 24 | 65.6% | -676.6% | ||
| Q1 24 | 48.8% | -662.4% |
| Q4 25 | $2.62 | $-0.17 | ||
| Q3 25 | $-1.84 | $-0.36 | ||
| Q2 25 | $-2.13 | $-0.41 | ||
| Q1 25 | $-2.21 | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | $-2.25 | $-0.34 | ||
| Q2 24 | $4.67 | $-0.40 | ||
| Q1 24 | $1.70 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $115.6M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $92.2M | $1.1B |
| 总资产 | $154.4M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $115.6M | $743.3M | ||
| Q3 25 | $44.9M | $659.8M | ||
| Q2 25 | $62.2M | $525.1M | ||
| Q1 25 | $77.2M | $500.5M | ||
| Q4 24 | $86.3M | $594.4M | ||
| Q3 24 | $101.2M | $427.6M | ||
| Q2 24 | $123.6M | $474.3M | ||
| Q1 24 | $137.8M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $92.2M | $1.1B | ||
| Q3 25 | $16.6M | $1.0B | ||
| Q2 25 | $34.1M | $919.1M | ||
| Q1 25 | $49.3M | $933.9M | ||
| Q4 24 | $56.4M | $1.0B | ||
| Q3 24 | $64.9M | $524.6M | ||
| Q2 24 | $74.7M | $584.4M | ||
| Q1 24 | $37.2M | $401.2M |
| Q4 25 | $154.4M | $1.5B | ||
| Q3 25 | $93.5M | $1.4B | ||
| Q2 25 | $108.9M | $1.3B | ||
| Q1 25 | $124.4M | $1.3B | ||
| Q4 24 | $136.4M | $1.4B | ||
| Q3 24 | $153.3M | $726.5M | ||
| Q2 24 | $165.8M | $775.9M | ||
| Q1 24 | $184.7M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-11.3M | $-47.3M |
| 自由现金流率自由现金流/营收 | -32.9% | -133.1% |
| 资本支出强度资本支出/营收 | 0.1% | 3.5% |
| 现金转化率经营现金流/净利润 | -0.56× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-11.3M | $-46.1M | ||
| Q3 25 | $-15.3M | $-117.4M | ||
| Q2 25 | $-20.3M | $-76.4M | ||
| Q1 25 | $-19.1M | $-132.0M | ||
| Q4 24 | $-58.4M | $-115.4M | ||
| Q3 24 | $-5.9M | $-59.2M | ||
| Q2 24 | $-14.9M | $-82.2M | ||
| Q1 24 | $-19.0M | $-102.3M |
| Q4 25 | $-11.3M | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $-20.3M | $-79.6M | ||
| Q1 25 | $-19.1M | $-133.8M | ||
| Q4 24 | $-58.7M | $-116.7M | ||
| Q3 24 | $-6.0M | $-63.8M | ||
| Q2 24 | $-14.9M | $-83.4M | ||
| Q1 24 | $-19.1M | $-109.0M |
| Q4 25 | -32.9% | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | -112627.8% | -413.9% | ||
| Q1 25 | -65917.2% | -907.4% | ||
| Q4 24 | -9199.8% | -2567.7% | ||
| Q3 24 | -1033.2% | -244.6% | ||
| Q2 24 | -29.9% | -578.5% | ||
| Q1 24 | -108.4% | -789.9% |
| Q4 25 | 0.1% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 11.1% | 16.4% | ||
| Q1 25 | 220.7% | 12.4% | ||
| Q4 24 | 39.2% | 28.6% | ||
| Q3 24 | 6.8% | 17.5% | ||
| Q2 24 | 0.1% | 8.2% | ||
| Q1 24 | 0.5% | 48.2% |
| Q4 25 | -0.56× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.45× | — | ||
| Q1 24 | -2.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
